Loss of HLA class I expression in prostate cancer: implications for immunotherapy (Q71576061)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

title

Loss of HLA class I expression in prostate cancer: implications for immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

author name string

Blades RA

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Keating PJ

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

McWilliam LJ

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

George NJ

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

language of work or name

English

0 references

publication date

1 November 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

page(s)

681-6; discussion 686-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

Changes in prostate cancer incidence and treatment in USA

19 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Molecular and cellular markers for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

A new look for the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Natural history of HLA expression during tumour development.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

The detailed distribution of HLA-A, B, C antigens in normal human organs

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Loss of MHC class-I expression in cervical carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

The biological consequences of altered MHC expression on tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Identification of human cancers deficient in antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

Natural history of localised prostatic cancer managed by conservative therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980301-X

7 January 2021

10.1016/S0090-4295(99)80301-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7495121%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference